Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/aff91a92-f349-4f02-b09d-27e5b52da83e/

XERS

Xeris Pharmaceuticals Inc
Chart
$6.18
Latest Week 2026-06-05
HealthcareDrug Manufacturers - Specialty & GenericSMALL
Snapshot 2026-06-07 · 0.0w · Fresh
0.44
OS Score
4.0%
Value
97.0%
Quality
79.0%
Momentum
7/9
F-Score
0.197
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
0 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
4.0%ile
P/E
91.4×
P/S
3.5×
P/B
84.4×
E/P
0.0109
FCF Yield
0.041
EBITDA/EV
0.037
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
97.00000000
/100 — 1=cheapest
VC2 (Trending Value)
99.00000000
/100
VC3 (Buyback)
99.00000000
/100
P/E of 91.4x is premium-priced — the market is paying up for expected growth. VC2 score of 99.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
97.0%ile
ROE
0.923
ROA
0.031
Net Margin
0.038
Op Margin
0.103
GPA
0.655
D/E
29.13
Current
2.12
F-Score
7/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.415
Stability
2.201
lower=better
Accruals
-0.093
lower=better
5yr Consist
No
ROE of 92% is exceptional. Highly leveraged with D/E of 29.13 — returns are being amplified by debt.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
79.0%ile
6M Return
-5.1%
12M Return
34.9%
12-1 Mom
42.6%
Risk-Adj
0.80
Vol 252d
52.9%
Vol 60d
107.0%
↑ Expanding
Max DD 12M
-44.3%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 43% is very strong — a clear uptrend. Near-term vol (107%) is expanding vs long-term (53%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.44
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
1.4%
Sector Quality %ile
98.6%
P/E z-score
1.19
P/B z-score
6.98
Sector Avg OS
63.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Quality Momentum — Expensive
Strong quality (97th) and momentum (79th) but expensive (4th value). Premium priced — watch for mean reversion.
Leveraged Returns
Strong ROE (92%) boosted by high leverage (D/E 29.1). Returns look good but come with balance sheet risk.
Quality at a Premium
High quality (97th) but expensive (4th value). Upside may be limited without earnings growth.
Volatility Expanding
60-day vol (107%) significantly exceeds 252-day (53%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
22.7% avg (7 factors)
Quality
C
56.3% avg (8 factors)
Momentum
C
59.6% avg (4 factors)
Risk
F
28.5% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.440—0—
Value %ile0.040—1—
Quality %ile0.970—1—
Momentum %ile0.790—1—
F-Score7.000—1—
Confidence0.939—1—
Volatility0.529—1—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
91.42
Earnings Yield (E/P)
0.0109
Price / Sales
3.49
Price / Book
84.37
Price / Cash Flow
22.62
FCF Yield
4.1%
EBITDA / EV
3.7%
Sales Yield (1/P·S)
0.2595
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
92.3%
Return on Assets
3.1%
Net Margin
3.8%
Operating Margin
10.3%
Gross Profit / Assets
Novy-Marx GPA
65.5%
Debt / Equity
29.13
Current Ratio
2.12
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.093
MomentumPrice trend strength over different horizons
6M Return
-5.1%
12M Return
34.9%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
42.6%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.80
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
41.5%
Earnings Stability (CV)
Lower = more stable
2.201
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
7
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
97
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
99
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
99
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity